No headlines found.
Business Wire (Mon, 3-Aug 8:00 AM ET)
Business Wire (Wed, 29-Jul 8:00 AM ET)
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
Estrella Immunopharma trades on the NASDAQ stock market under the symbol ESLA.
As of August 6, 2026, ESLA stock price was flat at $0.75 with 12,859 million shares trading.
ESLA has a beta of 3.05, meaning it tends to be more sensitive to market movements. ESLA has a correlation of 0.10 to the broad based SPY ETF.
ESLA has a market cap of $32.10 million. This is considered a Sub-Micro Cap stock.
The top ETF exchange traded funds that ESLA belongs to (by Net Assets): VTI, VXF, IWC.
ESLA has underperformed the market in the last year with a price return of -12.2% while the SPY ETF gained +23.6%. ESLA has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -47.0% and -2.0%, respectively, while the SPY returned +6.5% and +2.8%, respectively.
ESLA support price is $.68 and resistance is $.82 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ESLA shares will trade within this expected range on the day.
